Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

Fineline Cube Mar 9, 2025

NewCo is a new transaction model developed by Chinese innovative drug companies in response to...

Company

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development

Fineline Cube Mar 9, 2025

Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...

Company Deals

Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights

Fineline Cube Mar 7, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...

Company Drug

Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment

Fineline Cube Mar 7, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...

Company Drug

Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16

Fineline Cube Mar 7, 2025

China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...

Company Drug

Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease

Fineline Cube Mar 7, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Johnson & Johnson Terminate Phase III VENTURA Program for Aticaprant in adjunctive treatment of MDD

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III...

Company Drug

Gan & Lee Pharmaceuticals Joins Brazil’s PDP for Localized Insulin Production

Fineline Cube Mar 7, 2025

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced receiving a financial pledge of BRL130 million...

Company Drug

Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials

Fineline Cube Mar 7, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...

Company Deals

4C Medical Lands $175M Series D to Advance AltaValve TMVR System

Fineline Cube Mar 7, 2025

US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech...

Company

Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences

Fineline Cube Mar 7, 2025

German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a...

Company Deals

Astellas Pharma and YASKAWA Establish JV for Cell Therapy Product Manufacturing Platform

Fineline Cube Mar 7, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) is set to establish a joint venture (JV) with...

Company Drug

Johnson & Johnson Officially Launches Spravato in China for Depression Treatment

Fineline Cube Mar 7, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in...

Company Drug

Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA

Fineline Cube Mar 7, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...

Company Medical Device

Cryofocus Medtech’s Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market

Fineline Cube Mar 7, 2025

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement...

Company Deals Drug

Roche and JD Healthcare Collaborate on Influenza Prevention with Xofluza (Baloxavir Marboxil)

Fineline Cube Mar 7, 2025

Swiss giant Roche’s (SWX: ROG, OTCMKTS: RHHBY) China unit has entered into a collaboration agreement...

Company Drug

Suzhou GenAssist’s GEN6050X Receives FDA Clearance for Duchenne Muscular Dystrophy Treatment

Fineline Cube Mar 7, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd has announced receiving clearance from the US Food and...

Company Drug

BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies

Fineline Cube Mar 7, 2025

Zhejiang-based BioRay Biopharmaceutical has announced receiving clearance from the National Medical Products Administration (NMPA) to...

Company Drug

CStone Pharmaceuticals’ CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced a Phase Ib clinical filing in Australia for...

Company Drug

Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment

Fineline Cube Mar 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the US Food and...

Posts pagination

1 … 200 201 202 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.